Cencora (COR) has emerged onto the scene with its bold moves in the Q4 earnings season. The bio-tech company's shares were sold by multiple high-profile investors including
Wedge Capital and
Waycross Partners, but managed to find new patrons in
Matrix Trust Company,
Global X Japan Co. Ltd., and
SG Americas Securities. Despite some oscillation, Cencora's share price enjoyed an 8% rise in Q4. Cencora shows a substantial expansion by acquiring
EyeSouth Partners' retina business in an impressive $1.1 billion deal, though Vanguard subsequently disclosed it held no Cencora holdings. A recent price pullback has met with strong shareholder return, and Cencora's
earnings per share (EPS) forecasts remain firm at $17 despite a shake-up in leadership. Cencora garnered further interest through RSUs exercised by executive vice presidents and an undisclosed CFO. Investor reactions have been positive towards Cencora's strategic decision to deepen its disease services through collaboration with
Curant. A questioning stock market saw Cencora's shares fall after the integration of
OneOncology and the recent FY26 update. Still, the reassertion of fiscal year 2026 guidance brought some relief. Looking forward, Cencora is set to refocus on drug distribution following the divestiture of its animal health unit. Finally, Cencora has announced a CFO transition, with current financial chief set to retire in 2026.
Cencora COR News Analytics from Mon, 13 Oct 2025 07:00:00 GMT to Sat, 28 Mar 2026 12:38:10 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor -4
